Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Availability Of Inhaled Insulin Promotes Greater Perceived Acceptance Of Insulin Therapy In Patients With Type 2 Diabetes.

N. Freemantle, L. Blonde, D. Duhot, M. Hompesch, R. Eggertsen, F. Hobbs, L. Martinez, S. Ross, B. Bolinder, E. Stridde
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia (1,5–7). This randomized controlled trial examined the extent to which the availability of INH affects the perceived acceptability of insulin therapy among patients with type 2 diabetes who failed to achieve target glycemia on current therapy. Male or female participants ( n = 779) aged 35–80 years with at least 3 months duration of type 2 diabetes and a HbA1c >8%, despite current therapy, were recruited from seven countries. Permitted current therapy included dietary measures and/or oral antidiabetic agents (OADs). Patients receiving insulin injections, smokers, or those who had significant pulmonary diseases were excluded. All patients gave informed consent, and local research ethics review boards approved the study. Participants were randomly assigned to receive either educational information about the potential risks and benefits of all currently licensed treatment options only (OADs and/or subcutaneous insulin, n = 388) or information about the potential risks and benefits of licensed treatments and INH ( n = 391). …
This paper references



This paper is referenced by
10.1038/ncpendmet1007
Inhaled insulin—what went wrong
J. Mitri (2009)
10.2165/00019053-200826030-00005
Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
J. Chancellor (2012)
10.1007/BF03320927
Perfil farmacoeconómico de Exubera® en el tratamiento de la diabetes
C. Rubio-Terrés (2007)
10.1136/pgmj.2006.053868
Inhaled insulins
S. Ghosh (2007)
Glycaemic control with advanced new insulins for the treatment of diabetes
Aston Triangle (2006)
10.7326/0003-4819-144-7-200604040-00017
Efficacy and safety of inhaled insulin therapy.
L. Tosiello (2006)
Inhaled Insulin as alternative delivery system for subjects with diabetes – A literature review
(2009)
10.1016/S1579-2129(07)60148-7
Inhaled insulin and its effects on the lungs
E. Sarmiento (2007)
10.1310/hpj4106-560
Insulin Human (rDNA Origin) Inhalation Powder
Dennis J. Cada (2006)
10.1002/PDI.889
Needle‐free insulin: from dreams to reality
S. Bellary (2006)
Formulation and Evaluation of Insulin Dry Powder forPulmonary Delivery
Shivanand Pandey (2009)
Inhaled insulin: extending the horizons of inhalation therapy.
Vamsi P. Guntur (2007)
10.3109/08958378.2013.769037
Inhaled biopharmaceutical drug development: nonclinical considerations and case studies
Mary Mcelroy (2013)
10.1177/14746514060060030201
Review: Inhaled insulin: overcoming barriers to insulin therapy?
S. Bellary (2006)
10.1007/BF02849950
Drug delivery systems improve Pharmaceutical profile and facilitate medication adherence
A. Wertheimer (2005)
10.1111/j.1463-1326.2006.00647.x
Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof‐of‐concept study
M. Hausmann (2006)
10.1007/978-94-007-5971-8_3
Diabetes Mellitus: New Challenges and Innovative Therapies
C. Sena (2013)
10.1056/nejmct063533
Inhaled insulin for diabetes mellitus.
G. McMahon (2007)
10.1517/17425247.4.1.63
First approved inhaled insulin therapy for diabetes mellitus
R. Jani (2007)
10.1089/dia.2009.0115
Effect of technosphere inhaled insulin on quality of life and treatment satisfaction.
M. Peyrot (2010)
10.1002/EDN.56
Glycaemic control with advanced new insulins for the treatment of diabetes
C. Day (2006)
10.1016/j.jdiacomp.2007.05.001
The role of inhaled insulin in the treatment of type 2 diabetes.
S. Davis (2008)
10.3949/CCJM.73.6.569
Inhaled human insulin: an inspiration for patients with diabetes mellitus?
M. B. Davidson (2006)
10.1007/s40271-015-0160-x
A Systematic Review of Patients’ Perspectives on the Subcutaneous Route of Medication Administration
Colin H. Ridyard (2016)
10.1016/J.CLINTHERA.2007.06.003
Developing a pulmonary insulin delivery system for patients with diabetes.
G. Dailey (2007)
10.1016/S2213-8587(19)30005-1
Oral insulin: time to rewrite the textbooks.
C. Mathieu (2019)
10.1586/17512433.1.1.13
Inhaled human insulin (Exubera®): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus
K. Schimke (2008)
10.1111/j.1748-1716.2007.01789.x
Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs
S. Efendić (2008)
10.1111/jphp.12340
Developing accurate models of the human airways
L. J. Marshall (2015)
10.1056/NEJMCT063533
Inhaled insulin for diabetes mellitus.
E. V. Kriegstein (2007)
10.7326/0003-4819-143-8-200510180-00012
Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma
R. Comi (2005)
10.1007/s00125-006-0161-3
Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes
S. Garg (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar